[Asia Economy Reporter Hyungsoo Park] Pharmicell announced on the 9th that it will participate in the consortium for the vaccine raw and subsidiary materials production advancement technology development project led by the Ministry of Trade, Industry and Energy.
This project is aimed at developing GMP-grade production technology for high-purity nucleotides used in mRNA vaccine manufacturing, with the goal of securing global competitiveness through support for core raw and subsidiary material technology development for domestic mRNA vaccine development and production.
Through this task, Pharmicell will develop a chemical synthesis method for NMP (Nucleoside Monophosphate) and develop a manufacturing process for NTP (Nucleoside Triphosphate) using enzymes.
NTP is not only used in mRNA vaccine manufacturing but also applied in various fields such as genetic analysis research, increasing the importance of securing production technology.
A Pharmicell official stated, "Since COVID-19, research on mRNA-based vaccines has been actively conducted," adding, "We will develop chemical and biological synthesis processes based on the purification technology Pharmicell possesses." He continued, "By securing the manufacturing technology for NTP, the raw material of mRNA vaccines, we will play a key role in the global supply chain."
Pharmicell is currently conducting the ‘Development of manufacturing technology for deoxynucleoside triphosphate (dNTP) usable in molecular diagnostics and mass production technology for nucleic acid extraction reagents’ through the Pan-Government Full-Cycle Medical Device R&D Project led by the Ministry of Health and Welfare. Through this project, it has secured synthesis and purification technology for dNTP manufacturing and confirmed a purity of over 99%.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
